生命体征:人类免疫缺陷病毒检测、病毒抑制及HIV暴露前预防现状——美国,2013-2018年
CDC利用监测和药房数据分析美国2013-2018年HIV检测、病毒抑制和暴露前预防(PrEP)现状。2013年新发感染38,500例至2017年37,500例保持稳定(p=0.448)。2017年85.8%感染被诊断,42个辖区854,206例确诊者中62.7%病毒载量抑制。
要点
- 2013年新发HIV感染38,500例,2017年37,500例,保持稳定(p=0.448)。
- 2017年85.8%的HIV感染被诊断;42个辖区854,206例确诊者中62.7%病毒载量抑制。
核心结论
- 需要加速诊断、治疗和预防HIV感染的努力,以实现美国到2030年新发HIV感染至少减少90%的目标。
研究设计与样本
- CDC分析HIV监测数据估计2013-2017年年度新发HIV感染数、2017年感染诊断百分比及2017年确诊感染者病毒载量抑制百分比。
- CDC分析监测、药房和其他数据估计PrEP覆盖,计算为被处方PrEP人数除以估计有PrEP指征人数。
主要发现
- 新发HIV感染数从2013年38,500例至2017年37,500例保持稳定(p=0.448)。
- 2017年估计85.8%的感染被诊断。
- 在42个实验室数据报告完整的辖区,854,206例确诊HIV感染者中62.7%病毒载量抑制。
关键数值与推荐
- 目标:至少95%的HIV感染者获得诊断。
- 目标:至少95%的确诊HIV感染者病毒载量抑制。
- 目标:至少50%的HIV感染风险增加者被处方PrEP。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 38,000 new human immunodeficiency virus (HIV) infections occur in the United States each year; these infections can be prevented. A proposed national initiative, Ending the HIV Epidemic: A Plan for America, incorporates three strategies (diagnose, treat, and prevent HIV infection) and seeks to leverage testing, treatment, and preexposure prophylaxis (PrEP) to reduce new HIV infections in the United States by at least 90% by 2030. Targets to reach this goal include that at least 95% of persons with HIV receive a diagnosis, 95% of persons with diagnosed HIV infection have a suppressed viral load, and 50% of those at increased risk for acquiring HIV are prescribed PrEP. Using surveillance, pharmacy, and other data, CDC determined the current status of these three initiative strategies. METHODS: CDC analyzed HIV surveillance data to estimate annual number of new HIV infections (2013-2017); estimate the percentage of infections that were diagnosed (2017); and determine the percentage of persons with diagnosed HIV infection with viral load suppression (2017). CDC analyzed surveillance, pharmacy, and other data to estimate PrEP coverage, reported as a percentage and calculated as the number of persons who were prescribed PrEP divided by the estimated number of persons with indications for PrEP. RESULTS: The number of new HIV infections remained stable from 2013 (38,500) to 2017 (37,500) (p = 0.448). In 2017, an estimated 85.8% of infections were diagnosed. Among 854,206 persons with diagnosed HIV infection in 42 jurisdictions with complete reporting of laboratory data, 62.7% had a suppressed viral load. Among an estimated 1.2 million persons with indications for use of PrEP, 18.1% had been prescribed PrEP in 2018. CONCLUSION: Accelerated efforts to diagnose, treat, and prevent HIV infection are needed to achieve the U.S. goal of at least 90% reduction in the number of new HIV infections by 2030.
引用
- Harris NS, Johnson AS, Huang YA, et al. Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis - United States, 2013-2018. MMWR Morb Mortal Wkly Rep. 2019. PMID: 31805031. doi:10.15585/mmwr.mm6848e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。